Cefuroxime Shortage: A Provider-Focused Update for 2026

The intermittent shortage of Cefuroxime — particularly injectable formulations — continues to present challenges for healthcare providers across clinical settings. This guide offers a comprehensive overview of the current supply landscape, evidence-based therapeutic alternatives, and practical prescribing strategies to ensure patients maintain uninterrupted antibiotic therapy.

For the patient-facing version of this update, see Cefuroxime shortage update: what patients need to know in 2026.

Current Supply Status by Formulation

Cefuroxime Axetil Oral Tablets (250 mg, 500 mg): Multiple generic manufacturers remain active in this market. Availability is generally adequate at the national level, though regional spot shortages and distributor allocation limits persist. Pharmacies may experience intermittent difficulty sourcing specific strengths from their primary wholesaler.

Cefuroxime Axetil Oral Suspension (125 mg/5 mL, 250 mg/5 mL): Availability is more variable than tablets, with fewer manufacturers in this segment. Pediatric patients who require the suspension formulation may be disproportionately affected. Consider tablet alternatives for patients capable of swallowing pills.

Cefuroxime Sodium for Injection (750 mg, 1.5 g): Injectable cephalosporins have faced the most persistent supply disruptions since 2022. Manufacturing consolidation, FDA compliance remediation at key production facilities, and raw material sourcing challenges have contributed to intermittent shortages across multiple manufacturers. Hospital and health-system pharmacies should continue to monitor supply closely and maintain allocation protocols.

Root Cause Analysis

The Cefuroxime shortage reflects broader systemic vulnerabilities in the generic antibiotic supply chain:

• Manufacturing concentration: Fewer than five manufacturers account for the majority of U.S. Cefuroxime supply across all formulations. Single-point-of-failure risk remains high.
• API sourcing: Active pharmaceutical ingredients for cephalosporins are primarily manufactured in India and China, creating geopolitical and regulatory vulnerability.
• Economic disincentives: Low reimbursement rates for generic antibiotics ($11–$30 per course with discount pricing) reduce manufacturer motivation to maintain surge capacity or buffer stock.
• Regulatory remediation cycles: FDA facility inspections that identify deficiencies can trigger multi-month production shutdowns, with cascading effects across the supply chain.
• Demand-supply mismatch: Seasonal respiratory infection peaks create predictable demand surges that the supply chain lacks capacity to absorb.

For additional context on availability challenges, see why is Cefuroxime so hard to find.

Therapeutic Alternatives: Evidence-Based Substitution Guidance

When Cefuroxime is unavailable, the following alternatives are supported by clinical evidence for common indications. Selection should be based on the specific infection, local susceptibility patterns, patient allergies, and comorbidities.

Acute Bacterial Sinusitis

• First-line alternative: Amoxicillin-Clavulanate 875/125 mg PO BID × 5–7 days (IDSA guidelines)
• Cephalosporin alternative: Cefdinir 300 mg PO BID × 10 days or Cefpodoxime 200 mg PO BID × 10 days
• Penicillin allergy: Doxycycline 100 mg PO BID × 5–7 days or respiratory fluoroquinolone (reserve for patients without other options)

Acute Otitis Media

• First-line alternative: Amoxicillin 80–90 mg/kg/day (pediatric) or Amoxicillin-Clavulanate for treatment failure
• Cephalosporin alternative: Cefdinir 14 mg/kg/day PO × 10 days or Cefpodoxime 10 mg/kg/day PO × 5 days
• Third-line: Ceftriaxone 50 mg/kg IM × 3 days (for refractory cases)

Pharyngitis/Tonsillitis (Group A Strep)

• First-line: Penicillin V 500 mg PO BID × 10 days or Amoxicillin 50 mg/kg PO QD × 10 days
• Cephalosporin alternative: Cephalexin 500 mg PO BID × 10 days or Cefdinir 300 mg PO BID × 5–10 days
• Penicillin allergy (non-anaphylactic): Cephalexin or Cefdinir
• Severe penicillin allergy: Azithromycin or Clindamycin (based on local resistance data)

Early Lyme Disease (Erythema Migrans)

• Preferred alternative: Doxycycline 100 mg PO BID × 10–21 days (IDSA/AAN guidelines — also covers potential co-infections)
• Alternative for patients who cannot take Doxycycline: Amoxicillin 500 mg PO TID × 14–21 days
• Note: Cefdinir and Cefpodoxime are NOT well-studied for Lyme disease and should not be considered equivalent substitutes

Uncomplicated UTI

• First-line (per IDSA): Nitrofurantoin 100 mg PO BID × 5 days or Trimethoprim-Sulfamethoxazole DS PO BID × 3 days
• Cephalosporin alternative: Cefpodoxime 100 mg PO BID × 3–7 days or Cephalexin 500 mg PO BID × 5–7 days
• Note: Cefdinir is NOT recommended for UTIs

Skin and Soft Tissue Infections

• First-line: Cephalexin 500 mg PO QID × 7–10 days
• Alternatives: Dicloxacillin, Amoxicillin-Clavulanate, or Cefdinir depending on suspected pathogens

Prescribing Strategies During Shortage Periods

1. Verify availability before prescribing. Direct patients to Medfinder for Providers to check real-time pharmacy stock before committing to a Cefuroxime prescription. This reduces prescription abandonment and patient frustration.
2. Prescribe with flexibility. When clinically appropriate, indicate acceptable alternatives on the prescription or provide patients with a backup prescription for a therapeutic substitute.
3. Consider formulation flexibility. If 500 mg tablets are unavailable, two 250 mg tablets provide the same dose. Clarify this on the prescription when applicable.
4. Communicate proactively. Educate patients about the shortage and provide clear guidance on what to do if they can't fill their prescription. Share the Medfinder guide for finding Cefuroxime in stock with your patients.
5. Coordinate with pharmacy. Establish communication channels with your patients' pharmacies. Pharmacists can alert you when they can't fill a prescription and suggest available alternatives from their current stock.
6. Monitor treatment continuity. For patients on extended Cefuroxime courses (e.g., 20-day Lyme disease treatment), proactively plan for supply continuity by confirming pharmacy stock for the duration of therapy.

Stewardship Considerations

Shortages can lead to suboptimal antibiotic selection. As you navigate Cefuroxime alternatives:

• Avoid fluoroquinolone escalation when oral cephalosporin or penicillin alternatives exist
• Reference local antibiogram data when selecting alternatives, particularly for UTIs and respiratory infections
• Document shortage-driven substitutions in the patient record for care continuity
• Consider infectious disease consultation for complex cases where the preferred agent is unavailable

Resources for Providers

• ASHP Drug Shortage Database: ashp.org/drug-shortages — Manufacturer-level supply updates
• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages
• Medfinder for Providers — Real-time pharmacy stock verification tool
• How to help your patients find Cefuroxime in stock: a provider's guide
• How to help patients save money on Cefuroxime: a provider's guide

Related Patient Resources to Share

Consider directing affected patients to these guides:

• Cefuroxime shortage update: what patients need to know
• Alternatives to Cefuroxime if you can't fill your prescription
• How to find Cefuroxime in stock near you
• What is Cefuroxime: uses, dosage, and what you need to know
• Cefuroxime side effects: what to expect
• How to save money on Cefuroxime